



Patent Application
Attorney Docket No. PC10299A

#2
YC
8/14/01

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 6th day of August, 2001.

By

Kristina L. Konstas

(Signature of person mailing)
Kristina L. Konstas

(Typed or printed name of person)

RECEIVED
AUG 13 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: David S. Roberts, et al. :

APPLICATION NO.: 09/489,711 : Examiner: Hines, J.

FILING DATE: January 24, 2000 : Group Art Unit: 1645

TITLE: ERYSIPELOTHRIX RHUSIOPATHIAE :
ANTIGENS AND VACCINE
COMPOSITIONS

Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

1. Sato, H., et al., Protective Activity and Antigenic Analysis of Fractions of Culture Filtrates of Erysipelothrix Rhusiopathiae, Veterinary Microbiology, Vol. 43, No. 2-3, 1995, pp. 173-182.
2. Timoney J. F. And Groschup M. M., Properties of a Protective Protein Antigen of Erysipelothrix Rhusiopathiae, Veterinary Microbiology, Vol. 37, No. 3-4, 1993, pp. 381-387.
3. Kobayashi, S. et al., Immunological Characterization of Protective Antigens Prepared by Alkaline Treatment of Whole Cells and From the Culture Filtrate of Erysipelothrix, Veterinary Microbiology, Vol. 30, 1992, pp. 73-85.
4. Chemical Abstracts Service abstract of Takagi, H., et al., Recombinant Preparation of Protective Peptide Antigen and Use as Vaccine Against Erysipelothrix-Rhusiopathiae, Database Accession-No: 133:149129.
5. Groschup, M. H., et al., Characterization of a Protective Protein Antigen of Erysipelothrix Rhusiopathiae, Epidemiol. Infect., 107, 1991, pp. 637-649.

6. Sawada, T. And Takahashi, T., Cross Protection of Mice and Swine Inoculated with Culture Filtrate of Attenuated Erysipelothrix Rhusiopathiae and Challenge Exposed to Strains of Various Serovars, Am J Vet Res, Vol 48, No. 2, February 1987, pp. 239 - 242.

Items 1, 2, 3, and 4 listed above were cited in the partial European Search Report in the corresponding European patent application. A copy of the partial European Search Report is also submitted herewith. No other references have yet been cited by the European Patent Office.

Applicants also hereby disclose to the Examiner copending U.S. patent application Serial No. 09/489,713, filed January 24, 2000, entitled "ADJUVANTS FOR USE IN VACCINES", claiming priority of U.S. 60/117,705, filed January 29, 1999, and U.S. 60/121,760, filed February 26, 1999. It is believed the Examiner has access to 09/489,713, for consideration when examining the present case. However, if the Examiner does not have access to 09/489,713, applicants kindly request that the Examiner notify applicants' undersigned attorney.

The Examiner is requested to consider carefully the complete text of the aforementioned references and documents in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicants' belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references and documents.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee is believed necessary for filing this Information Disclosure Statement. However, if any fee is found necessary in connection with filing this Information Disclosure Statement, authorization is hereby given to charge such fee to Deposit Account No. 16-1445

A prompt and favorable response is earnestly solicited.

Date: August 6, 2001

Respectfully submitted,

Kristina L. Konstas
Kristina L. Konstas
Attorney for Applicant(s)
Reg. No. 37,864

Pfizer Inc
Patent Department, 20th Floor
235 East 42nd Street
New York, NY 10017-5755
(212) 733-6380